
==== Front
Cancer Biol Med
Cancer Biol Med
CBM
Cancer Biology & Medicine
2095-3941
Compuscript Ireland

j.issn.2095-3941.2024.0201
10.20892/j.issn.2095-3941.2024.0201
Editorial
SETD2 in cancer: functions, molecular mechanisms, and therapeutic regimens
Weng Yawen
https://orcid.org/0000-0002-6497-1792
Xue Jing
https://orcid.org/0000-0002-4210-0136
Niu Ningning
State Key Laboratory of Systems Medicine for Cancer, Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
Correspondence to: Jing Xue and Ningning Niu, E-mail: jingxue@sjtu.edu.cn and niuningning@shsmu.edu.cn
15 9 2024
19 9 2024
21 9 725730
06 6 2024
13 8 2024
Copyright: © 2024 The Authors
2024
The Authors
https://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.
National Natural Science Foundation of China82073105 National Natural Science Foundation of China32370833 State Key Laboratory of Systems Medicine for CancerKF2412 This work was supported by the National Natural Science Foundation of China (Grant Nos. 82073105 and 32370833) and the State Key Laboratory of Systems Medicine for Cancer (Grant No. KF2412).
==== Body
pmcIn recent years, the histone methyltransferase SET domain containing 2 (SETD2) has garnered significant attention for its involvement in carcinogenesis. Herein we aim to summarize the research advances regarding SETD2 in tumors, elucidate the role in global epigenetic regulation, highlight potential therapeutic regimens for patients with SETD2 deficiency, and outline future research directions.

SETD2 catalyzes protein methylation

SETD2 primarily catalyzes trimethylation of histone H3 at lysine 36 (H3K36me3) from H3K36me2 within gene body regions to guarantee transcription elongation1. Deficiency of SETD2-H3K36me3 restrains transcription of critical tumor suppressor genes and establishes a direct correlation between SETD2-H3K36me3 and carcinogenesis. SETD2 protein includes the SET domain responsible for methyltransferase activity, the post-SET domain that enhances catalytic activity, the WW domain involved in protein-protein interactions, and the SRI domain that interacts with RNA polymerase II. These domains collectively enable SETD2 to recognize and bind the histone H3 tail, which catalyzes H3K36me31.

In addition, the SETD2-H3K36me3 level is closely related to other types of epigenetic modifications to change chromatin accessibility2,3. Our previous studies revealed that SETD2-H3K36me3 deficiency facilitates H3K27me3 and H3K27Ac ectopic gain, which contributes to immune escape and metabolic reprogramming in pancreatic ductal adenocarcinoma (PDAC)2,3. SETD2-H3K36me3 also enhances recruitment of the DNA methyltransferase DNMT3B to gene bodies. The epigenetic interplay involving SETD2, H3K36me3, DNA methyltransferase 3 beta (DNMT3B), and DNA methylation ensures the fidelity of gene transcription initiation with implications for intragenic hypomethylation in cancer4. In addition, H3K36me3 is recognized and directly bound by the m6A methyltransferase, methyltransferase-like protein 14 (METTL14), guiding global m6A deposition co-transcriptionally5.

Non-histone proteins are also SETD2 substrates. SETD2 mediates methylation of lysine 525 on signal transducer and activator of transcription 1 (STAT1), enhancing IFNα-dependent antiviral immunity6. Additionally, SETD2 methylates lysine 735 on enhancer of zeste homolog 2 (EZH2), which suppresses prostate cancer metastasis7. SETD2 is also necessary for p53 tumor suppressor interactions8. Researchers are currently using novel techniques, such as the amino acid specificity profile, to delve deeper into the specific substrate sequences of SETD2. It is anticipated that these approaches will uncover and elucidate novel substrates and functions of SETD2 in the future.

SETD2 mutations and/or copy number variation (CNV) are widespread in various tumor types

SETD2 is frequently mutated or deleted to alter the epigenetic landscape by causing depletion of H3K36me3 in a variety of tumors, including hematologic malignancies9, clear cell renal cell carcinoma (ccRCC)10, colorectal cancer (CRC)11,12, prostate cancer (PCa)7, and PDAC2,3,13. Among the pan-cancer cohort comprised of 10,953 patients in the cancer genome atlas (TCGA), 521 (4.76%) were shown to harbor SETD2 mutations3. These mutations mainly include missense, inframe, and truncating mutations, structural variants, copy number deep deletions, and a small number of amplifications. Additionally, SETD2 gene inactivating mutations are directly associated with the survival and prognosis of certain tumors. For example, a high frequency of SETD2 gene inactivating mutations is more frequently found in late-stage ccRCC. These mutations are associated with a higher and earlier risk of recurrence as well as poorer survival outcomes14. Our previous studies showed that SETD2 is mutated in 3%–8% of PDAC patients with low expression in 33%–50% of PDAC patients2,3,13. These studies have demonstrated that the loss of the SETD2-H3K36me3 axis leads to epigenetic changes that reshape tumor cell metabolism and the immune microenvironment, showing a unique influence on the development and progression of PDAC.

SETD2 deficiency promotes tumor progression through multiple pathways

SETD2 regulates tumor cell intrinsic phenotypes

Cell fate encompasses various processes, such as cell proliferation, differentiation, senescence, death, and migration. These processes determine physiologic functions and are critical in pathologic conditions, including developmental malformations and cancer. The mechanisms underlying cell fate determination are fundamental in biology. Studies have demonstrated that intrinsic changes within cells, such as genetic mutations and epigenetic disorders, and extrinsic environmental signals, such as cytokines and metabolic changes, are crucial regulatory factors.

SETD2 loss enhances the self-renewal ability of NHD13+ hematopoietic stem and progenitor cells (HSPCs), leading to increased symmetric self-renewal division and decreased cell differentiation and cell death. This acceleration in self-renewal and altered cell fate contributes to the transformation of myelodysplastic syndromes (MDSs) into acute myeloid leukemia (AML)9. Additionally, SETD2 deficiency induces a polycomb-repressive chromatin state, which enables cells to acquire metastatic traits in PCa7. A recent follow-up study indicated that SETD2 loss impairs the DNA damage response (DDR) following exposure to cytotoxic chemotherapy, resulting in reduced apoptosis15. SETD2 is also a key regulator of epithelial–mesenchymal transition (EMT) phenotypes. Inactivation of SETD2 drives EMT and promotes migration, invasion, and stemness in a transforming growth factor-beta-independent manner11,14.

Our study extensively investigated the dynamic dual role of SETD2 in epithelial cell fate transition using a pancreatic tumor model. During the initiation of pancreatic cancer, SETD2-H3K36me3 deficiency elevates MYC expression through downregulation of FBXW7, affecting acinar homeostasis maintenance and facilitating KRAS-induced acinar-to-ductal metaplasia (ADM). Additionally, SETD2-H3K36me3 deficiency enhances EMT and tumor metastasis by sustaining AKT activation and downregulating α-catenin levels13.

SETD2 deficiency reprograms tumor metabolism

Tumor cell metabolism is often remodeled, which helps tumors adapt to the microenvironment and enhance tumor growth. Coincidentally, SETD2 deficiency has been widely demonstrated to induce metabolic reprogramming in various tumors. The loss of SETD2 promotes extensive sphingomyelin biosynthesis during the transition from polycystic kidney disease (PKD) to ccRCC10. In hepatocellular carcinoma (HCC), SETD2-H3K36me3 deficiency downregulates the expression of cholesterol efflux-related genes, leading to lipid accumulation and tumor hyperprogression16. Furthermore, SETD2 is crucial for maintaining intestinal epithelial homeostasis, thereby mitigating the development of colitis and colorectal cancer by regulating oxidative stress and the reactive oxygen species (ROS) level12. Our recent studies revealed that SETD2 deficiency accelerates pancreatic carcinogenesis by remodeling various metabolic pathways. SETD2 deficiency reprograms glycolytic metabolism to compensate for insufficient nucleoside synthesis17. SETD2-deficient PDAC increases glycolysis addiction by upregulating GLUT1 to meet glucose demands and impairs nucleoside synthesis by downregulating TKT in the pentose phosphate pathway. In contrast, pancreatic tumor cell-intrinsic SETD2 deficiency drives the formation of a lipid-rich stroma, upregulating lipid metabolic genes and enhancing fatty acid β-oxidation (FAO) and oxidative phosphorylation (OXPHOS). This SETD2 loss also unleashes BMP2 signaling through ectopic H3K27Ac gain, causing cancer-associated fibroblasts (CAFs) to differentiate into a lipid-rich phenotype. These lipid-laden CAFs then promote tumor progression by supplying lipids for mitochondrial oxidative phosphorylation via the ABCA8a transporter2.

SETD2 deficiency reshapes the tumor immune microenvironment (TIME)

The highly heterogeneous TIME has a vital role in tumor initiation, progression, immune evasion, and response to therapy. Tumor cell-intrinsic alterations, such as genetic mutations and epigenetic disorders, sculpt the TIME by reprogramming surrounding immune cells. Pancreatic tumor cell-intrinsic SETD2 inactivation reprograms and activates CD8+ T cell-mediated killing18. Liu reported higher levels of CD4+ T cells and reduced M2 macrophage infiltration in SETD2-mutated RCC patients compared to SETD2 wild-type patients19. Our previous study revealed that SETD2 deficiency significantly enhances neutrophil recruitment and reprogramming, leading to reduced cytotoxicity of CD8+ T cells. This immune modulation facilitates immune escape and promotes pancreatic tumor progression3.

SETD2 deficiency modulates CAF heterogeneity

As crucial components of the tumor microenvironment (TME), CAFs have pivotal roles in tumor initiation, metastasis, metabolic reprogramming, immune evasion, and drug resistance. Given the complex function of CAFs, scRNAseq has confirmed the presence of myofibroblast CAFs (myCAFs), inflammatory CAFs (iCAFs), and antigen-presenting CAFs (apCAFs) in mouse and human pancreatic tumors. By analyzing pancreatic tumors with different mutations and morphology, additional CAF types were identified. During early tumor initiation, reciprocal tumor-stroma signaling drives the reprogramming of progenitor cells to CAFs. In addition, CAF heterogeneity in fate and function is spatially regulated by signals derived from genetically diverse tumor cells and tumor microenvironment conditions. Our study demonstrated that the loss of SETD2 induces epigenetic reprogramming and unleashes BMP signaling, fostering the differentiation of a lipid-laden CAF subpopulation marked by ABCA8a. These ABCA8a+ lipid-laden CAFs metabolically sustain tumor cell OXPHOS and tumor growth by transporting lipids. These findings illuminate the role of SETD2 loss in reshaping CAFs to support tumor energy demands2.

In summary, SETD2 has a pivotal role in regulating tumor progression through diverse mechanisms (Figure 1). Our recent systematic research analyzed SETD2 function and the mechanism by which SETD2 regulates pancreatic tumorigenesis from multiple perspectives, including tumor cell fate, immune microenvironment, CAF heterogeneity, and metabolic remodeling2,3,13,17. These findings suggest that tumor cells possess remarkable abilities to choose different strategies to maintain survival and development, and adapt to adverse diverse environmental conditions. This exploration of the multiple effects of epigenetic mutations and disorders enhances our understanding of tumor characteristics and offers promising avenues for the development of novel patient-tailored precision therapies.

Figure 1 Multiple molecular pathways, cellular functions, and biological processes regulated by SETD2. CAF, cancer-associated fibroblast; EMT, epithelial–mesenchymal transition; TIME, tumor immune microenvironment; OXPHOS, oxidative phosphorylation.

Current status of therapeutic regimens for SETD2-deficient tumors

As a tumor suppressor, SETD2 mutations and copy number variations are widespread in diverse tumor types, suggesting the significance of developing patient-tailored therapies based on SETD2-H3K36me3 deficiency. However, there are currently no small-molecule drugs that can compensate for the loss of SETD2 and/or H3K36me3, thus limiting therapeutic options. Therefore, by elucidating the molecular and mechanistic pathways using mouse, cell, and patient-derived xenograft (PDX) models, researchers have proposed a series of precise alternative treatment options for SETD2-deficient tumors (Figure 2 and Table 1).

Figure 2 Potential alternative therapies for patients with SETD2 deficiency.

Table 1 Summary of therapeutic strategies

Therapeutic strategy	Biological function	Cancer type	Reference	
Immunotherapy: anti-PD-1/PD-L1	Blockage of immune checkpoint	Pancreatic ductal adenocarcinoma	18	
Immunotherapy: anti-Ly6G	Neutrophil depletion	Pancreatic ductal adenocarcinoma	3	
Epigenetic inhibition: JQ1	Inhibition of BET protein	Pancreatic ductal adenocarcinoma	2	
Metabolic restriction: OXPHOSi (Gboxin)	Glycolysis inhibition	Pancreatic ductal adenocarcinoma	2	
Metabolic restriction: GLUT1i (STF31)	Glycolysis inhibition	Pancreatic ductal adenocarcinoma	17	
Chemotherapy: Ara-C	Cell cycler checkpoint	Acute myeloid leukemia	20	
Chemotherapy: WEE1i (MK-1775)	Cell cycler checkpoint	Acute myeloid leukemia	20	
Chemotherapy: WEE1i (MK-1775)	Cell cycler checkpoint	Renal cancer and other cancer types	21	
Chemotherapy: ATRi (VE822)	DNA damage	Renal cell carcinoma	19	
Chemotherapy: PARPi talazoparib (BMN-673)	DNA damage	Clear-cell renal cell carcinoma	22	
Chemotherapy: DNA HMA 5-aza-2′-dexoxydytidine (DAC)	DNA damage	Clear-cell renal cell carcinoma	22	

Chemotherapy remains a cornerstone in the treatment of various cancers, with ongoing research efforts aimed at enhancing effectiveness and identifying suitable patient cohorts. The loss of SETD2-H3K36me3 has emerged as a sensitive indicator of drug responsiveness. Given the role of SETD2 in DNA methylation and damage repair, a combination therapy strategy using DNA hypomethylating agents (HMAs) and PARP inhibitors (PARPis) may exhibit potent antitumor effects in SETD2-deficient renal cell carcinoma22. According to Dong et al.20, combining S and G2/M checkpoint inhibition with chemotherapy offers a promising therapeutic strategy. This approach effectively resensitizes chemo-resistant acute leukemia (AL) cases with SETD2 mutations by targeting unique vulnerabilities20. Our recent study elucidated the mechanistic underpinnings of how SETD2 deficiency induces reprogramming of glycolytic metabolism to compensate for inadequate nucleoside synthesis. This finding suggests that restricting glycolysis in combination with gemcitabine could be a promising therapeutic approach for PDAC patients with SETD2 deficiency17.

Synthetic lethality offers a strategy for targeting genetic defects in cancer. A previous study showed that WEE1 inhibition selectively kills H3K36me3-deficient cancer cells by targeting a ribonucleotide reductase subunit (RRM2) as the synthetic lethal interaction21. SETD2-H3K36me3 safeguards RRM2 transcription, while WEE1 inhibition degrades RRM2 through untimely CDK activation. WEE1 inhibition in H3K36me3-deficient cells results in RRM2 reduction, critical dNTP depletion, S-phase arrest, and cell death21.

Our study revealed that cultured SETD2-deficient pancreatic tumor cells increase glycolytic flux to compensate for insufficient nucleoside synthesis and support tumor growth. Consequently, glycolysis inhibition via STF-31 has potential as an effective tumor suppression strategy17. Notably, intratumoral SETD2-deficient cells manifest dramatically strengthened OXPHOS and remodeled H3K27Ac distribution due to the additional lipid provided by surrounding CAFs. Using a mouse model and PDX models from pancreatic cancer patients, our recent study demonstrated that pancreatic tumors with low levels of SETD2/H3K36me3 are associated with increased sensitivity to S-Gboxin and JQ1 compared to pancreatic tumors with high H3K36me3 levels2.

Recent studies have highlighted the significance of TIME heterogeneity as an intrinsic trait of tumor cells. The loss of SETD2, known for its pivotal roles in DNA damage repair, genomic stability maintenance, and mRNA splicing, results in accumulation of tumor mutation-specific neoantigens on the cell surface. Bioinformatic analysis and research have suggested a potential link between SETD2 and the efficacy of immune checkpoint inhibitor (ICI) immunotherapy3,19. Additionally, Zheng et al.18 concluded that cancer patients with SETD2 mutations undergoing ICI treatment are associated with improved durable clinical outcomes and survival rates. SETD2 inactivation reprograms intratumoral immune cells, leading to increased tumor inflammation characterized by increased T cell infiltration and enhanced antigen presentation18. This process activates CD8+ T cell-mediated killing18. Our previous investigation provided mechanistic insight into how tumor cell-intrinsic SETD2 deficiency promotes neutrophil recruitment and reprograms toward an immunosuppressive phenotype during pancreatic tumorigenesis. These findings offer potential therapeutic implications for pancreatic cancer patients with SETD2 deficiency3.

Conclusions

SETD2 is generally considered a tumor suppressor with mutations or CNV in many tumors. SETD2 deficiency accelerates tumor initiation, progression, metastasis, and escape from immune surveillance. Multiple investigations have revealed the multiple molecular functions of SETD2, including influencing tumor cell fate, regulating cellular metabolic balance, remodeling the TIME, and interacting with stromal cells. A deeper understanding of the SETD2 role in tumor progression is crucial for future advances in the diagnosis, precision therapies, alternative therapies, and prevention of cancer for PDAC patients with SETD2 deficiency.

Conflict of interest statement

No potential conflicts of interest are disclosed.

Author contributions

Writing original draft: Yawen Weng and Ningning Niu.

Modify the manuscript: Ningning Niu.

Proofread the manuscript: Jing Xue and Ningning Niu.

All authors read and approved the final manuscript.
==== Refs
References

1. Edmunds JW Mahadevan LC Clayton AL Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation EMBO J 2008 27 406 20 18157086
2. Niu N Shen X Wang Z Chen Y Weng Y Yu F Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer Cancer Cell 2024 42 869 84.e9 38579725
3. Niu N Shen X Zhang L Chen Y Lu P Yang W Tumor cell-intrinsic SETD2 deficiency reprograms neutrophils to foster immune escape in pancreatic tumorigenesis Adv Sci (Weinh) 2023 10 e2202937 36453584
4. Neri F Rapelli S Krepelova A Incarnato D Parlato C Basile G Intragenic DNA methylation prevents spurious transcription initiation Nature 2017 543 72 7 28225755
5. Huang H Weng H Zhou K Wu T Zhao BS Sun M Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally Nature 2019 567 414 9 30867593
6. Chen K Liu J Liu S Xia M Zhang X Han D Methyltransferase SETD2-mediated methylation of STAT1 is critical for interferon antiviral activity Cell 2017 170 492 506.e14 28753426
7. Yuan H Han Y Wang X Li N Liu Q Yin Y SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways Cancer Cell 2020 38 350 65.e7 32619406
8. Carvalho S Vitor AC Sridhara SC Martins FB Raposo AC Desterro JM SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint Elife 2014 3 e02482 24843002
9. Chen BY Song J Hu CL Chen SB Zhang Q Xu CH SETD2 deficiency accelerates mds-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in mds Blood 2020 135 2271 85 32202636
10. Rao H Liu C Wang A Ma C Xu Y Ye T SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer Nat Commun 2023 14 7572 37989747
11. Ma C Liu M Feng W Rao H Zhang W Liu C Loss of SETD2 aggravates colorectal cancer progression caused by smad4 deletion through the ras/erk signalling pathway Clin Transl Med 2023 13 e1475 37962020
12. Liu M Rao H Liu J Li X Feng W Gui L The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis Redox Biol 2021 43 102004 34020310
13. Niu N Lu P Yang Y He R Zhang L Shi J Loss of SETD2 promotes kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis Gut 2020 69 715 26 31300513
14. Wang T Wagner RT Hlady RA Pan X Zhao X Kim S SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner Mol Oncol 2024 18 44 61 37418588
15. Mar BG Chu SH Kahn JD Krivtsov AV Koche R Castellano CA SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia Blood 2017 130 2631 41 29018079
16. Li XJ Li QL Ju LG Zhao C Zhao LS Du JW Deficiency of histone methyltransferase set domain-containing 2 in liver leads to abnormal lipid metabolism and HCC Hepatology 2021 73 1797 15 33058300
17. Shen X Chen Y Liu M Shi J Tang Y Yang X Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer Biochem Biophys Res Commun 2022 615 9 16 35679751
18. Zheng X Luo Y Xiong Y Liu X Zeng C Lu X Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway J Immunother Cancer 2023 11 e007678 38056895
19. Liu XD Zhang YT McGrail DJ Zhang X Lam T Hoang A SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma Clin Cancer Res 2023 29 4002 15 37527013
20. Dong Y Zhao X Feng X Zhou Y Yan X Zhang Y SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints Leukemia 2019 33 2585 98 30967619
21. Pfister SX Markkanen E Jiang Y Sarkar S Woodcock M Orlando G Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation Cancer Cell 2015 28 557 68 26602815
22. Zhou X Sekino Y Li HT Fu G Yang Z Zhao S SETD2 deficiency confers sensitivity to dual inhibition of DNA methylation and parp in kidney cancer Cancer Res 2023 83 3813 26 37695044
